151 related articles for article (PubMed ID: 19096882)
1. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
Abernethy AP; Barbour SY; Uronis H; Zafar SY; Coan A; Rowe K; Pupa MR; Wheeler JL; Herndon JE
Support Care Cancer; 2009 Jun; 17(6):735-44. PubMed ID: 19096882
[TBL] [Abstract][Full Text] [Related]
2. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
3. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
4. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
6. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.
Lyman GH
J Natl Compr Canc Netw; 2005 Jul; 3(4):557-71. PubMed ID: 16038646
[TBL] [Abstract][Full Text] [Related]
7. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
J Natl Compr Canc Netw; 2007 Feb; 5(2):217-28. PubMed ID: 17335690
[TBL] [Abstract][Full Text] [Related]
8. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
Nirenberg A; Reame NK; Cato KD; Larson EL
Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
10. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
11. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
12. The importance of prophylactic management of chemotherapy-induced neutropenia.
Repetto L; Accettura C
Anticancer Drugs; 2003 Oct; 14(9):725-30. PubMed ID: 14551505
[TBL] [Abstract][Full Text] [Related]
13. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
Lyman GH
Curr Opin Hematol; 2011 Jan; 18(1):1-10. PubMed ID: 21042215
[TBL] [Abstract][Full Text] [Related]
14. Prechemotherapy assessment of neutropenic risk.
Doyle AM
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):32-9; discussion 39-40. PubMed ID: 18153977
[TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
16. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
17. Risks and consequences of chemotherapy-induced neutropenia.
Lyman GH
Clin Cornerstone; 2006; 8 Suppl 5():S12-8. PubMed ID: 17379159
[TBL] [Abstract][Full Text] [Related]
18. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.
Wilson BJ; Gardner AE
Oncol Nurs Forum; 2007 Mar; 34(2):347-53. PubMed ID: 17573299
[TBL] [Abstract][Full Text] [Related]
19. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
20. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
Kearney N; Friese C
Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]